>> Update – this structure has been revised from the butyl amide – This is (i believe) the correct structure >>
Archive for the ‘Merck DE’ Category
Posted by kinasepro on February 13, 2007
Neeto – looks like they resolve the enantiomers via:
Even neeter-0 they show a couple xenos
Posted by kinasepro on October 17, 2006
Hello there Merck KGaA,
Nice Chk1 application. This one’s a modification of a previous GSK application WO2006072354 [Thats glycogen synthase kinase, not glaxo (I know, kinasepro wishes one of them would change their name too)]
This functional group is not without precedent, occuring in BMY25368 a histamine H2-receptor antagonist and elsewhere in the medicinal chemistry patentscape. Notably Schering and Wyeth seem to be all over the functional group for the last 25 years. Not so much in Kinases, but somebody in Pearl River must like them because American Cyanimide, American Home Products, and Wyeth have all messed around with them quite a bit through their history. They describe them as alpha-amino acid isosteres: J. Med. Chem. 1998, 236.
I guess KP shouldn’t be surprised to find the group has been used before for kinase inhibitors. It doesn’t seem like anyone has taken them very far, but OSI has a series of derivatives that hit c-Kit WO2006034111, and Abbott tried to use them as a urea mimic in a series of PP1 analogs: US20040014756.
Posted by kinasepro on October 10, 2006
Hi Merck KgAa,
Yours is another one of those patent applications that has Kinaspro thinking “this has got to be covered somewhere, by someone”
So did Bayer/Onyx not exemplify the N-Me Carboxamide in their earlier work?
Wont’ ya Go-
and… umm… well… Maybe you could just walk down the hall and poke someone in the eye for me?
No, I guess there’s no need for that, they did indeed claim a handful of disubstituted pryazoles. (RAF: WO199932106, WO199932110, WO199932111, and TrkA WO2005110994), Seems to Kinasepro that these partygoers are a few years late particularly when Merck is doing what Bayer did back in 1999, and BI did first with BIRB796 and then also later with (US6492529), hell even Kirin Beer has one of these: (WO2002088110)
Wait did someone say Kirin Beer?
So Merck think’s they’ve found a way around the Bayer patent estate, and must have some kind of PK / CYP / Drug-like-property / selectivity bump that’s not obvious. They’ve got something similar going on in: WO2006040056 where they are clearly looking at one-offs of Nexavar. You have to remember these are those Crazy-evil-genius-brilliant-German Merck types…
Hmmm, so what’s new in these patents? Well, one of the claims is on TIE2, and you can tell by the Markush they are only attempting to make very narrow claims around the two Pyrazole substituents. I didn’t translate all the structure names, but it appears there are a number of furans exemplified with a handful of other R group modifications. The one example they draw a structure for:
Of note Deciphera has 2 similar applications which published in July. WO2006071940, and WO2006081034 they are labelled VEGF/PDGF/Bcr-Abl applications
And the companies with advanced Angiogenesis programs that any potential candidate has to beat:
Bayer……… Check (http://www.nexavar.com)
Pfizer…….. Check (http://www.sutent.com/)
Astra-Zeneca.. Check (http://www.zactima.net/)
Genentech….. Check (http://www.avastin.com)
Bristol-Myers Squibb, Novartis, Glaxo, Roche, Amgen, Kirin Brewing Company, check, check, checkitty, check, check, check – yah, he did say Kirin Beer.
Posted by kinasepro on October 4, 2006
Hello Crazy Germans, errr I mean Hi Merck KGaA.
While everyone else is making pyrimidines, quinazolines, and assorted one or two-offs here comes Merck with umm this:?
I guess they look a little like the CDK compounds from J. Med. Chem. 2006, 44, 4628, but not really.
Kinaspro’s German isn’t all that good, but it looks as though they too speak Kinese: